OBJECTIVES: Haemophilia A is a genetic disorder characterized by deficiency in factor VIII (FVIII), how frequently a person bleeds and its severity depends on how much FVIII is in the plasma. Consequently, severe Haemophilia A is a lifelong condition that requires treatment with exogenous FVIII. Reduction of bleeding and chronic joint disease is achieved by prophylactic treatment. Several recombinant FVIII products (BAY 81-8973 and BIIB-031) have been recently approved introducing new dose frequency intervals. The aim of this study is to compare prophylactic treatments costs of recombinant FVIII products. METHODS: The annual costs have been calculated according to the different prophylactic doses of recombinant FVIII products, based on the Summary of Product Characteristics (SmPCs), for adults and adolescents aged 12 and over, with an average weight of 70kg. The number of units of FVIII is expressed in International Units (IU). Prophylactic treatment with BAY 81-8973 (20-40 IU/kg, 2-3 times weekly) was compared to prophylactic treatment with BIIB-031 (50 IU/kg, every 3-5 days) and rAHF-PFM (20-40 IU/kg, intervals of 2-3 days). The analysis was conducted from the Spanish National Health System perspective in a 1-year time horizon. Costs were based on the price per IU established in the reference price group in 2017 Euro (€). RESULTS: Over the time horizon evaluated, average prophylaxis cost per year was estimated at €180,739.10 with BAY 81-8973 treatment, compared with €211,441.58 for BIIB-031 and €211,441.58 for rAHF-PFM. CONCLUSIONS: The analysis conducted in this study concludes that the estimated annual prophylactic treatment of severe haemophilia A with BAY 81-8973 could be less expensive than other recombinant FVIII product at the same price per IU.